precision medicine

Research in Review

Breast Cancer Drug Shows Benefit in HER2-Positive Colorectal Cancer

05/05/2016

JCP Editors

Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic colorectal cancer may benefit from a targeted therapy regimen used to treat HER2-positive breast cancer with no need for added...

...

05/05/2016

Journal of Clinical Pathways

Algorithm Improves Adverse Event Response for Patients Receiving Immunotherapies

05/02/2016

JCP Editors

A standard algorithm created by a nurse-led collaborative team helped clinicians better assess and manage adverse events in patients receiving immunotherapy for cancer, according to an oral presentation at the...

A...

05/02/2016

Journal of Clinical Pathways

Research in Review

Neratinib Delays Recurrence With Fewer Metastases in Patients With Breast Cancer

04/29/2016

JCP Editors

Results from a phase 2 clinical trial showed that combination neratinib and paclitaxel treatment better managed central nervous system progression versus trastuzumab and paclitaxel in patients with ERBB2-positive...

...

04/29/2016

Journal of Clinical Pathways

Nivolumab More than Doubles One-Year Overall Survival in Head/Neck Cancer

04/27/2016

JCP Editors

Treatment with nivolumab reduced the risk of death and improved one-year overall survival (OS) compared with investigator’s choice of therapy for patients with recurrent or metastatic head and neck squamous cell...

...

04/27/2016

Journal of Clinical Pathways

Genetic Biomarkers Predict Treatment Outcomes for Patients With Breast Cancer

04/25/2016

JCP Editors

Results from a clinical trial presented at the 2016 American Association for Cancer Research Annual Meeting (April 16-20; New Orleans, LA) identified two genetic biomarkers capable of predicting which patients with...

...

04/25/2016

Journal of Clinical Pathways

Research in Review

Head-to-Head Trial Compares Outcomes With EGFR+ NSCLC Treatments

04/18/2016

JCP Editors

Early results of a head-to-head trial comparing two prominent treatments for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) could have a significant impact on clinical decision making for...

Early...

04/18/2016

Journal of Clinical Pathways

Research in Review

Blood Biopsy Test Ready for Use in Patients With NSCLC

04/14/2016

JCP Editors

A newly developed “liquid biopsy” assay that detects free-floating DNA from cells in blood plasma may be an effective tool for detecting mutations in patients with non-small cell lung cancer (NSCLC), according to the...

A...

04/14/2016

Journal of Clinical Pathways

Value and Precision Medicine

04/11/2016

JCP Editors

During her presentation at CANCERSCAPE, Kavita Patel, MD, MS, senior fellow at the Brookings Institution (Washington, DC), explained that, to physicians, personalized medicine doesn’t seem like something you have to...

During...

04/11/2016

Journal of Clinical Pathways

Research in Review

Human Epidermal Growth Factor Receptor-2 a Strong Indicator of Breast Cancer Prognosis

04/11/2016

JCP Editors

Human epidermal growth factor receptor-2 (HER-2) expression may be a key indicator of recurrence risk in patients with breast cancer, though PIK3CA mutations have no prognostic value, according to a recent...

Human...

04/11/2016

Journal of Clinical Pathways

Research in Review

Novel Precision Medicine Tool Effective for Tracking Mutation-Specific Patient Outcomes

04/08/2016

JCP Editors

Researchers have developed a novel tool for calculating and displaying the survival statistics of patients with cancer depending on their genetic profile, which could help practitioners to better track...

...

04/08/2016

Journal of Clinical Pathways